BOLT · Bolt Biotherapeutics, Inc.
$3.35
+0.14 (+4.36%)
At close · Aug 14
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Under our current operating plans, we believe our cash and cash equivalents and marketable securities of $18.1 million as of June 30, 2026 may be sufficient to fund our operations into first quarter 2027. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 11, 2026
Market Cap
$6.45M
Shares
1.93M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.7M
+0.1%
FY2025
Net Income
-$33.38M
+47.1%
FY2025
Operating Margin
-469.3%
+480.6pp
FY2025
Diluted EPS
-$17.85
+46%
FY2025
Operating Cash Flow
-$39.85M
+35%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $4.7M | $7.7M | $7.69M | $7.88M | $5.73M | $1.26M | $231K | |
| $21.5M | $28.53M | $57.47M | $61.54M | $73.12M | $75.66M | $40.36M | |
| $11.67M | $13.8M | $18.46M | $22.53M | $22.93M | $18.39M | $9.06M | |
| — | $1.29M | $1.78M | $1.85M | $1.67M | $1.19M | $611K | |
| — | $1.48M | $3.34M | $0 | — | — | — | |
| $35.46M | $43.81M | $80.74M | $84.07M | $96.05M | $94.05M | $49.41M | |
| -$30.76M | -$36.11M | -$73.05M | -$76.2M | -$90.32M | -$92.79M | -$49.18M | |
| — | -469.3% | -949.91% | -967.45% | -1576.56% | -7364.13% | -21290.91% | |
| — | -$34.82M | -$71.27M | -$74.34M | -$88.66M | -$91.6M | -$48.57M | |
| $2.02M | $2.74M | $9.93M | $7M | $2.22M | -$5.8M | -$11.55M | |
| — | -$33.38M | -$63.12M | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$28.74M | -$33.38M | -$63.12M | -$69.2M | -$88.1M | -$98.59M | -$60.73M | |
| — | -433.74% | -820.78% | -878.58% | -1537.76% | -7824.68% | -26289.18% | |
| -$28.78M | -$33.49M | -$63.06M | -$68.24M | -$88.7M | -$98.91M | -$60.73M | |
| USD/shares | — | -$17.85 | -$33.06 | -$36.60 | -$47.20 | -$59.40 | — |
| USD/shares | — | -$17.85 | -$33.06 | -$36.60 | -$47.20 | -$59.40 | — |
| shares | — | 1.87M | 1.91M | 1.89M | 1.87M | 1.66M | 99.46K |
| shares | — | 1.87M | 1.91M | 1.89M | 1.87M | 1.66M | 105.12K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.62×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 170 similar-size Biotechnology companies (of 545 listed).